Sign up for our daily briefing
Make your busy days simpler with Axios AM/PM. Catch up on what's new and why it matters in just 5 minutes.
Stay on top of the latest market trends
Subscribe to Axios Markets for the latest market trends and economic insights. Sign up for free.
Sports news worthy of your time
Binge on the stats and stories that drive the sports world with Axios Sports. Sign up for free.
Tech news worthy of your time
Get our smart take on technology from the Valley and D.C. with Axios Login. Sign up for free.
Get the inside stories
Get an insider's guide to the new White House with Axios Sneak Peek. Sign up for free.
Catch up on coronavirus stories and special reports, curated by Mike Allen everyday
Catch up on coronavirus stories and special reports, curated by Mike Allen everyday
Want a daily digest of the top Denver news?
Get a daily digest of the most important stories affecting your hometown with Axios Denver
Want a daily digest of the top Des Moines news?
Get a daily digest of the most important stories affecting your hometown with Axios Des Moines
Want a daily digest of the top Twin Cities news?
Get a daily digest of the most important stories affecting your hometown with Axios Twin Cities
Want a daily digest of the top Tampa Bay news?
Get a daily digest of the most important stories affecting your hometown with Axios Tampa Bay
Want a daily digest of the top Charlotte news?
Get a daily digest of the most important stories affecting your hometown with Axios Charlotte
Photo: Olivier Douliery/AFP via Getty Images
Gilead Sciences CEO Daniel O’Day said in an open letter Saturday that the company is expanding access to its experimental anti-coronavirus drug remdesivir to include severely ill COVID-19 patients.
The big pig picture: President Trump has called the antiviral drug "promising," but the results of six clinical trials on this investigational medicine are still being conducted, so its effectiveness in the treatment of the novel coronavirus has yet to be proved. The World Health Organization is involved in the tests.
"With expanded access, hospitals or physicians can apply for emergency use of remdesivir for multiple severely ill patients at a time."— Excerpt from O’Day's statement
- Gilead Sciences temporarily stopped granting emergency access requests for remdesivir from individual patients outside the trials "due to an overwhelming demand" last Sunday.
Zoom in: The firm has moved from its "compassionate use" program to one of "expanded access" because "the system cannot support and process the overwhelming number of applications we have seen with COVID-19," O'Day said.
- Children and pregnant women would still have access via the "compassionate use" program, which has seen the drugmaker provide remdesivir to more than 1,000 patients, per O'Day's letter.
- Establishing the safety and efficacy of this investigational medicine is essential before it can be distributed for use worldwide, O'Day noted.
What's next: The company hopes to have initial data from the trials in the coming weeks.
- "If it is approved, we will work to ensure affordability and access so that remdesivir is available to patients with the greatest need," O'Day said.
Go deeper: